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Background: Radioiodine is routinely used or proposed for diagnostic and therapeutic purposes: 123I, 125I and 131I
for diagnostics and 125I and 131I for therapy. When radioiodine-labelled pharmaceuticals are administered to the
body, radioiodide might be released into the circulation and taken up by the thyroid gland, which may then be an
organ at risk. The aim of this study was to compare dosimetric properties for 123I, 125I and 131I in previously developed
thyroid models for man, rat and mouse.
Methods: Dosimetric calculations were performed using the Monte Carlo code MCNPX 2.6.0 and nuclear decay
data from ICRP 107. Only the non-radiative transitions in the decays were considered. The S value was determined
for the cell nuclei in species-specific thyroid follicle models for mouse, rat and man for different spatial distributions of
radioiodine.
Results: For the species-specific single follicle models with radioiodine homogeneously within the follicle lumen, the
highest S value came from 131I, with the largest contribution from the β particles. When radioiodine was homogeneously
distributed within the follicle cells or the follicle cell nucleus, the highest contribution originated from 125I, about two
times higher than 123I, with the largest contribution from the Auger electrons. The mean absorbed dose calculated for
our human thyroid multiple follicle model, assuming homogenous distribution of for 123I, 125I, or 131I within the follicle
lumens and follicle cells, was 9%, 18% and 4% higher, respectively, compared with the mean absorbed dose according
to Medical Internal Radiation Dose (MIRD) formalism and nuclear decay data. When radioiodine was homogeneously
distributed in the follicle lumens, our calculations gave up to 90% lower mean absorbed dose for 125I compared to MIRD
(20% lower for 123I, and 2% lower for 131I).
Conclusions: This study clearly demonstrates the importance of using more detailed dosimetric methods and models
than MIRD formalism for radioiodine, especially 123I and 125I, in the thyroid. For radioiodine homogeneously distributed
in the follicle lumens our calculations for the human multiple follicle models gave up to 90% lower mean absorbed dose
compared with MIRD formalism.
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Radioiodine has been used clinically for about 70 years,
both for diagnosis (123I, 125I and 131I) and therapy (125I
and 131I) of various diseases. Radioiodine is to a high ex-
tent accumulated in the thyroid gland and metabolically
built into the thyroid hormones, and the biokinetics of
radioiodine is used for measurement of thyroid function
[1]. 131I, as iodide, is therefore routinely used for diagno-
sis and treatment of various thyroid disorders such as* Correspondence: anders.josefsson@radfys.gu.se
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tion, and reproduction in any medium, providethyrotoxicosis (hyperthyroidism) and thyroid cancer [1-3].
Lately, 131I has sometimes been replaced by 123I as iodide
for diagnostic purposes to avoid the thyroid stunning
phenomenon [4,5]. Radioiodine bound to specific vector
molecules is also widely used. For example, 131I- and 123I-
MIBG are used for scintigraphy and 131I- and 125I-MIBG
for treatment of various neuroendocrine tumours [6,7],
123I-receptor ligands for brain scintigraphy [8], 125I methy-
lene blue for sentinel node localization [9] and 131I-labelled
monoclonal antibodies for treatment of lymphoma [10].
When, radioiodine labelled pharmaceuticals are adminis-
tered to the body, radioiodide might be released into theee Springer. This is an Open Access article distributed under the terms of the
reativecommons.org/licenses/by/4.0), which permits unrestricted use, distribu-
d the original work is properly credited.
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tissues, and taken up by the thyroid gland [11]. For radio-
pharmaceuticals or tracers labelled with radioiodine, the
thyroid is thus an organ at risk.
Furthermore, 131I is a radionuclide of importance in
nuclear accidents, where it is a rest product from the
nuclear fission process in nuclear energy plants. After
the Chernobyl accident in 1986, contamination with 131I
(and other short-lived isotopes such as 132I and 133I) led
to an increased incidence of differentiated thyroid can-
cers in children but not in adults, with a higher inci-
dence with lower age [12-15].
There is thus a need for accurate dosimetric calcula-
tions of the absorbed dose for both patients examined or
treated with radioiodine, personnel handling radioiodine
and for personnel and the general population in case of
accidental exposure to radioiodine.
Dosimetric estimations using the MIRD formalism is
mostly utilised due to its simplicity, and the use of mean
absorbed dose is of interest if the radionuclides and the
energy deposited are homogeneously distributed within
each organ/tissue. This assumption is adequate as long
as the range of the emitted particles is long compared to
the size of the cells. For radionuclides emitting particles
with shorter range, e.g. Auger and internal conversion
electrons, non-uniform distribution within an organ/tis-
sue will give heterogeneous absorbed dose distribution,
and more detailed dosimetric approaches are clearly
needed.
The physical properties differ between these radioio-
dine isotopes. For 131I, emitting relatively high-energy β
particles with a range up to 2 mm in tissue [16], the en-
ergy distribution will be relatively homogeneous within
the thyroid, less dependent of the radionuclide distribu-
tion, while for 125I, emitting cascades of Auger electrons
with ranges from a few nanometres up to around 23 μm
in tissue, the energy deposition within the thyroid gland
will be more heterogeneous, dependent of the distribu-
tion of the radionuclide, electrons emitted, half-life, and
the amount of photons emitted [17,18].
To be able to determine more detailed dosimetric
parameters for the thyroid cells from heterogeneously
distributed radioiodine isotopes in the thyroid tissue,
thyroid tissue models are needed. We have recently
published thyroid models for man, but also for mouse
and rat, and performed microdosimetric studies of the
α particle emitting radiohalogen 211At, demonstrating
the importance of detailed dosimetry for the thyroid
[19]. A few thyroid models for radioiodine dosimetry
have been previously published for normal and thyro-
toxic thyroid follicles [20-24]. To our knowledge, few
dosimetric studies have been published demonstrating
the dosimetric properties of these radioiodine nuclides
in these models.The aim of this study was to compare dosimetric cal-
culations for 123I, 125I and 131I using the general purpose
Monte Carlo radiation transport code MCNPX 2.6.0
[25] with nuclear decay data from ICRP 107 [26] and the
recently developed thyroid models for man, rat and
mouse [19].
Methods
The radioiodine isotopes 123I, 125I and 131I
Nuclear decay data from ICRP 107 for 123I, 125I and 131I
were used in all the dosimetric calculations, if not
stated otherwise [26]. Only the non-radiative (NR) tran-
sitions from Auger and Coster-Kronig electrons (denoted
AE in the rest of the paper), internal conversion electrons
(CE) and β particles were considered. The conventional
AE spectrum was used, and AE with initial kinetic ener-
gies <1 keV were assumed to be fully absorbed within the
source volume.
123I has a half-life of 13 h and decays by electron cap-
ture (EC) via 123Te (half-life 6.0 × 1014 years and yield
99.9996%) or 123mTe (half-life 119 days and yield 4.4 ×
10-5%) to stable 123Sb. 123I emits CE with 246 possible
initial kinetic energies and on average 14 AE per decay.
The mean emitted energy per decay for AE with initial
kinetic energies <1 keV is 1.25 keV [26].
125I has a half-life of 59 days and decays by EC to
stable 125Te. 125I emits CE with six possible initial kin-
etic energies and on average 23 AE per decay. The mean
emitted energy per decay for AE with initial kinetic ener-
gies <1 keV is 2.11 keV [26].
131I has a half-life of 8.0 days and decays by emission
of β particles directly or via 131mXe (half-life 11.8 days
and yield 1.18%) to stable 131Xe. The full energy
spectrum for the emission of β particles was considered,
including all six independent transition spectra. 131I
emits CE with 108 possible initial kinetic energies and
on average 0.7 AE per decay. The mean emitted energy
per decay for AE with initial kinetic energies <1 keV is
78.3 eV [26]. The contribution from 131mXe was not
considered in the dosimetric calculations.
Monte Carlo calculations
Calculations were performed using the general purpose
Monte Carlo radiation transport code MCNPX 2.6.0 [25]
on a MacBook Pro with a 2.66 GHz Intel Core 2 Duo pro-
cessor with Mac OS X version 10.6.8 (Apple Incorporated,
Cupertino, CA, USA). The tally *F8 was used, which gives
the energy imparted to the target volume. The default set-
tings in MCNPX were used for the sampling frequency,
and the cutoff energy was 1 keV. For each geometric
setup, 1 to 5 × 107 histories were simulated, depending on
geometry, distribution and NR transition. The default par-
ticle transport physics were used in the electron transport
calculations, which included multiple scattering, straggling
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electrons [27].
Single thyroid follicle model
The single thyroid follicle model used has previously been
described [19]. Briefly, the model consists of a single layer
of thyroid follicular cells surrounding a spherical follicle
lumen (diameter 10 to 500 μm). The follicle cells have a
thickness of 6, 8 or 10 μm with a centrally located spher-
ical nucleus with diameters of 4, 6 and 8 μm, respectively.
For the species-specific models, the follicle lumen diam-
eter, follicle cell thickness and nucleus diameter are: (1)
50, 6 and 4 μm for mouse, (2) 70, 8 and 6 μm for rat and
(3) 150, 10 and 8 μm for man, respectively. All the follicle
models were assumed to consist of liquid water with unit
density (1.0 g/cm3). The radioiodine distributions investi-
gated were (A) homogeneous distribution within the fol-
licle lumen, (B) homogeneous distribution on concentric
spherical surfaces in the follicle lumens, (C) homogeneous
distribution within the follicle cells and (D) homogeneous
distribution within the follicle cell nuclei. In all simula-
tions, the targets were the six follicular cell nuclei sym-
metrically positioned on the Cartesian axes, and the result
was the average value for these targets (cf. [19]).
Multiple thyroid follicle models
A multiple thyroid follicle model was used to calculate
the contribution from surrounding layers of follicles to the
follicle cell nuclei in a centrally placed follicle, based on
the previously published multiple follicle model [19]. Cal-
culations were performed for the models of mouse, rat
and man. The neighbouring follicles were modelled as one
surrounding layer of follicle cells, one outer layer simulat-
ing the follicle lumens with the respective thickness: (1) 6
and 50 μm for the mouse, (2) 8 and 70 μm for the rat and
(3) 10 and 150 μm for the human model and another sur-
rounding layer of follicle cells. The number of surrounding
follicle layers that contributed depended on the species and
radioiodine isotopes and was two, one and eight for 123I,
125I and 131I, respectively, in the human model.
In this model, two radioiodine distributions were used:
(E) homogeneous distribution within the surrounding
follicle lumens and (F) homogeneous distribution within
the surrounding follicle cells. The targets were the six
follicle cell nuclei in the central follicle, similar to the
single follicle model (cf. [19]).
Dosimetric parameters
MIRD formalism was used to calculate the mean
absorbed dose, D(rT), using the expression
D rTð Þ ¼
~A rS;TDð Þ
M rTð Þ ⋅
X
i
Ei⋅Y i⋅ϕ rT←rSð Þ Gy½  ð1Þwhere ~A rS;TDð Þ is the time-integrated activity (accord-
ing to MIRD pamphlet no. 21, previously named cumu-
lated activity in MIRD primer), in the source volume in
units of Bq⋅s, M(rT) is the mass of the target volume in
units of kilogrammes [28,29]. Ei ⋅ Yi, is the mean electron
energy per transformation (26.7, 16.5 and 191.2 keV for
123I, 125I and 131I, respectively according to web pub-
lished MIRD decay data [30]), and ϕ(rT← rS) is the
absorbed fraction in the target volume for the emitted
electrons per nuclear transformation, and was assumed
to be unity for 123I, 125I and 131I in the thyroid gland of
man.
The cumulative specific activity, ~C rS;TDð Þ, is expressed
as
~C rS;TDð Þ ¼
~A rS;TDð Þ
M rTð Þ Bq⋅s=kg½  ð2Þ
To achieve a calculated mean absorbed dose of 1 Gy
to the thyroid gland according to MIRD formalism
(Equation 1), a ~C rS;TDð Þ equal to 234, 378 and 32.6
TBq⋅s/kg was needed for 123I, 125I and 131I, respectively.
The mean absorbed dose can also be calculated using
the expression
D rTð Þ ¼ ~A rS;TDð Þ⋅S rT←rSð Þ Gy½  ð3Þ
where S(rT← rS) is the mean absorbed dose per unit cu-
mulated activity in the source volume in units of Gy/
Bq⋅s [29] and will be denoted as the S value in the con-
tinuation of the text.
Results
Single follicle model
Radioiodine in species-specific follicle thyroid models
For the mouse, rat and human models, the calculated S
values with radioiodine homogeneously distributed within
the follicle lumen are shown in Table 1. For the mouse
model, the S value was 280% and 110% higher for 131I than
that for 123I and 125I, respectively. The largest contribution
originated from the β particles for 131I (88%) and a similar
contribution from the AE and CE for 123I and 125I. For the
rat model, the S value was 340% and 230% higher for 131I
than that for 123I and 125I, respectively. The largest contri-
bution originated from the β particles for 131I (90%) and
from the CE for 123I (63%) and 125I (55%). For the human
model, the S value was 310% and 650% higher for 131I than
that for 123I and 125I, respectively. The largest contribution
originated from the β particles for 131I (93%) and from the
CE for 123I (87%) and 125I (60%).
For the mouse, rat and human models, the calculated
S values with radioiodine homogeneously distributed
within the follicle cells are shown in Table 1. For the
mouse model, the S value for 131I was 10% and 60%
lower than that for 123I and 125I, respectively. The largest
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(86%) and from the AE for 123I (90%) and 125I (68%). For
the rat model, the S value for 131I was 6% higher and
50% lower than that for 123I and 125I, respectively. The
largest contribution originated from the β particles for
131I (87%) and from the AE for 123I (87%) and 125I (67%).
For the human model, the S value for 131I was 20%
higher and 40% lower than that for 123I and 125I, respect-
ively. The largest contribution originated from the β par-
ticles for 131I (89%) and from the AE for 123I (81%) and
125I (67%).
For the mouse, rat and human models, the calculated
S values with radioiodine homogeneously distributed
within the follicle cell nucleus are shown in Table 1. For
the mouse model, the S value for 131I was 80% and 90%
lower than that for 123I and 125I, respectively. The largest
contribution originated from the β particles for 131I
(71%) and from the AE for 123I (98%) and 125I (72%). For
the rat model, the S value for 131I was 70% and 90%
lower than that for 123I and 125I, respectively. The largest
contribution originated from the β particles for 131I
(76%) and from the AE for 123I (98%) and 125I (71%). In
the human model, the S value for 131I was 60% and 80%
lower than that for 123I and 125I, respectively. The largest
contribution originated from the β particles for 131I
(79%) and from the AE for 123I (97%) and 125I (71%).
Comparison with previously published cellular S values
Comparison between the calculated S values for 123I, 125I
and 131I homogeneously distributed within the follicle cell
nuclei with 4, 6 and 8 μm diameter calculated in the
present study and previously published cellular S values
by Goddu and Budinger [31] gave the following results:
for 123I, the previously published S values were 1.3%, 2.9%
and 2.4% higher, for 125I, 0.07%, 0.99% and 0.53% higher
and for 131I, 2.1%, 1.5% and 0.71% higher, respectively.
Radioiodine homogeneously distributed within the follicle
lumen in human model
For the 8-μm diameter follicle cell nuclei, the calculated
S values with 123I, 125I and 131I homogeneously distrib-
uted within the follicle lumen are shown as a function of
the follicle lumen diameter in Figure 1. For the smallest
follicle lumen diameter (10 μm), 125I gave the highest S
value, 30% and 120% higher than that for 131I and 123I,
respectively. For larger follicle lumens, 131I gave the
highest S value, 350% and 2,000% higher (500 μm) than
that for 123I and 125I, respectively (Figure 1a). For 123I,
the relative contributions from AE and CE were 42%
and 58% and 5% and 95% for 50-μm and 500-μm lumen
diameter, respectively (Figure 1b). For 125I, the relative
contributions from AE and CE were 42% and 58, and
39% and 61% for 50-μm and 500-μm lumen diameter, re-
spectively (Figure 1c). For 131I, the relative contributionsfrom the β particles, AE and CE were 88%, 11% and 0.6%
and 96%, 4% and 0.1% for 50-μm and 500-μm lumen
diameter, respectively (Figure 1d).
Radioiodine heterogeneously distributed within the
human thyroid follicle model
The S values were calculated for 123I, 125I and 131I homoge-
neously distributed on concentric spherical shells in the
human model to investigate effects of a heterogeneous dis-
tribution (Figure 2). The S values were almost constant
when 123I was situated inside the central follicle lumen due
to the CE (Figure 2a). When 123I was situated on the apical
follicle cell surface, the contributions from the AE and CE
were similar and 200% higher than when 123I was situated
in the centre of the central follicle lumen. The contribution
from 123I outside the central follicle decreased with in-
creasing radius. When 125I was situated in the centre of the
follicle lumen, the S values were zero until about 20 μm
from the apical follicle cell surface due to the short range
of emitted AE and CE (Figure 2b). When 125I was situated
on the apical follicle cell surface, the contribution from the
AE was slightly higher, with 56% compared with 44% from
the CE. The S value increased somewhat when 131I was sit-
uated peripherally in the lumen compared to that in the
centre of the follicle lumen (Figure 2c). The highest contri-
bution originated from the β particles irrespectively of lo-
cation and was 120% higher when 131I was situated on the
apical cell surface compared when centrally situated in the
follicle lumen. The contribution from 131I outside the fol-
licle decreased with increased radius.
Multiple thyroid follicle models
Contribution from surrounding follicle layers in the
human model
The calculated S values and the relative contributions to
the mean absorbed dose to the inner follicle cell nuclei
are presented in Table 2 with 123I, 125I and 131I homoge-
neously distributed within various source compartments
(the follicle lumens and cells) in the human multiple
thyroid follicle model (S values for the mouse and rat
models, see Additional file 1). When 123I was homoge-
neously distributed in the entire model, the contribution
to the mean absorbed dose from the central follicle was
37%. When 125I was homogeneously distributed in the
entire model, the contribution to the mean absorbed
dose from the central follicle was 90%. Due to the short
range of the AE and CE, only one surrounding follicle
layer contributed. When 131I was homogeneously dis-
tributed in the entire model, the contribution to the
mean absorbed dose from the central follicle was 11%.
The central follicle and eight surrounding follicle layers
contributed with approximately 99% of the absorbed
dose, with the largest contribution of approximately 30%
from the first surrounding follicle layer.
Table 1 S values for radioiodine in the species-specific single follicle models
β particles CE AE Total
S value Relative contribution S value Relative contribution S value Relative contribution S value
(Gy/Bq·s) (%) (Gy/Bq·s) (%) (Gy/Bq·s) (%) (Gy/Bq·s)
Nucleus← Lumen
Mouse
123I - - 1.23E-6 47.9 1.33E-6 52.1 2.56E-6
125I - - 2.49E-6 53.6 2.16E-6 46.4 4.66E-6
131I 8.56E-6 88.2 1.07E-6 11.0 7.74E-8 0.8 9.71E-6
Rat
123I - - 6.81E-7 62.7 4.06E-7 37.3 1.09E-6
125I - - 8.05E-7 55.1 6.57E-7 44.9 1.46E-6
131I 4.27E-6 89.8 4.63E-7 9.7 2.38E-8 0.5 4.75E-6
Man
123I - - 2.20E-7 86.7 3.39E-8 13.3 2.54E-7
125I - - 8.16E-8 59.8 5.49E-8 40.2 1.37E-7
131I 9.60E-7 93.3 6.71E-8 6.5 2.13E-9 0.2 1.03E-6
Nucleus← Follicle cells
Mouse
123I - - 1.79E-6 10.2 1.58E-5 89.8 1.76E-5
125I - - 1.24E-5 32.1 2.62E-5 67.9 3.86E-5
131I 1.34E-5 86.2 1.25E-6 8.0 9.03E-7 5.8 1.56E-5
Rat
123I - - 9.64E-7 13.0 6.47E-6 87.0 7.43E-6
125I - - 5.18E-6 32.6 1.07E-5 67.4 1.59E-5
131I 6.87E-6 87.4 6.23E-7 7.9 3.66E-7 4.7 7.86E-6
Man
123I - - 3.05E-7 19.1 1.29E-6 80.9 1.60E-6
125I - - 1.06E-6 32.9 2.15E-6 67.1 3.21E-6
131I 1.76E-6 89.0 1.45E-7 7.3 7.28E-8 3.7 1.98E-6
Nucleus← Nucleus
Mouse
123I - - 3.52E-4 1.7 2.06E-2 98.3 2.10E-2
125I - - 1.38E-2 28.5 3.45E-2 71.5 4.83E-2
131I 3.48E-3 70.9 2.18E-4 4.4 1.21E-3 24.7 4.91E-3
Rat
123I - - 1.58E-4 2.4 6.40E-3 97.6 6.56E-3
125I - - 4.35E-3 28.9 1.07E-2 71.1 1.51E-2
131I 1.52E-3 76.3 9.74E-5 4.9 3.74E-4 18.8 1.99E-3
Man
123I - - 9.03E-5 3.1 2.82E-3 96.9 2.91E-3
125I - - 1.93E-3 29.1 4.70E-3 70.9 6.63E-3
131I 8.44E-4 79.4 5.56E-5 5.2 1.63E-4 15.4 1.06E-3
The S value and the relative contribution from the non-radiative transitions β particles, Auger electrons (AE) and internal conversion electrons (CE) to the follicle
cell nucleus are given for the species-specific models of mouse, rat and man. 123I, 125I and 131I were homogeneously distributed within the follicle lumen, follicle
cells and follicle cell nucleus.















































































































Figure 1 The S value for homogeneous distribution of radioiodine in the lumen of the human single follicle model. The S value and the
relative contributions from the non-radiative transitions for homogeneously distributed radioiodine within the follicle lumen. The follicle lumen
diameter varied from 10 to 500 μm surrounded by one single layer of follicle cells with a thickness of 10 μm and centrally placed 8 μm diameter
follicle cell nucleus. (a) The S value for the follicle cell nucleus for 123I (square), 125I (triangle) and 131I (circle), as a function of the follicle lumen
diameter. (b to d) The relative contribution per decay to the follicle cell nucleus from Auger electrons (AE) (triangle), internal conversion electrons
(CE) (square), β particles (diamond), as a function of the follicle lumen diameter, for (b) 123I, (c) 125I and (d) 131I. Error bars indicate the standard
deviation of the mean value (SD) and are smaller than the symbol when not visible. Note the logarithmic scale on the ordinate in (a).
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model of man – comparison with MIRD formalism
To obtain a mean absorbed dose of 1 Gy to the cell nuclei
from homogeneously distributed for 123I, 125I and 131I, in
the human multiple follicle model using MIRD formalism
and nuclear decay data, the cumulative specific activities
~C rS;TDð Þ
 
equal to 234, 378 and 32.6 TBq⋅s/kg, respect-
ively, are needed. Using the same ~C rS;TDð Þ in the MC
simulations, the mean absorbed dose to the central follicle
cell nuclei with radioiodine homogeneously distributed
within the follicle lumens and follicle cells was 1.09, 1.18
and 1.04 Gy for 123I, 125I and 131I, respectively, in our mul-
tiple thyroid follicle models.
The mean absorbed dose to the central follicle cell nuclei
for various fractions of radioiodine distributed in the cellsversus lumens are shown in Figure 3. The mean absorbed
dose was 0.80 Gy ( ~C rS;TDð Þ = 267 TBq⋅s/kg) when 123I
was homogeneously distributed within the follicle lumens
only, while it was 3.1 Gy ( ~C rS;TDð Þ = 1,860 TBq⋅s/kg)
when 123I was located within the follicle cells only. For 125I,
the corresponding results were 0.11 Gy ( ~C rS;TDð Þ =
440 TBq⋅s/kg) and 7.8 Gy ( ~C rS;TDð Þ = 2,700 TBq⋅s/kg),
and for 131I 0.98 Gy ( ~C rS;TDð Þ = 37 TBq⋅s/kg) and
1.5 Gy (~C rS;TDð Þ = 276 TBq⋅s/kg).Discussion
In general, the S values determined in the present study
were in good agreement with the few corresponding data
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Figure 2 The S value for heterogeneous distribution of radioiodine in the human follicle model. The S value for the follicle cell nuclei
from the non-radiative transitions are given for homogeneously distributed (a) 123I, (b) 125I and (c) 131I on concentric spherical shells in the human
thyroid model. The contribution from Auger electrons (AE) (triangle), internal conversion electrons (CE) (square) and β particles (diamond) are
shown separately together with the total value (circle). The surface source radius 0 μm indicates the centre of the follicle lumen, and the dashed
lines represent the apical and basal follicle cell surfaces for the respective models. Error bars indicate the standard deviation of the mean value
(SD) and are smaller than the symbol when not visible. Note the logarithmic scale on the ordinate.
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in the species-specific models were in excellent agreement
with published cellular S values calculated with an analyt-
ical method [31] based on the experimental range-energy
relationship for electrons by Cole [32].
The mean absorbed dose to the follicle cells for 131I
homogeneously distributed within the follicle lumens
was determined for a similar human thyroid follicle
model as ours [24]. Their model included interstitial tis-
sue (51% of the total tissue volume), and 12 surrounding
follicles layers, compared with no interstitial tissue and
8 follicle layers in our human model (since we found
that the contribution from surrounding layers beyond
the 8th was <1%). The contribution from the central fol-
licle was 7% in our model compared with 17% in their
model, and the contribution from the surrounding follicles
in our model was slightly higher, e.g. 32% for the firstsurrounding layer compared with 29%. These differences
could mainly be explained by the difference in consider-
ation of interstitial tissue. Despite these model differences
we found in both studies that the follicle cells received
0.98 Gy when the mean absorbed dose was 1 Gy to thy-
roid tissue.
There are some simplifications and assumptions made
in the calculations, both for the mathematical models
and for physical data. The use of unit density water
(1.0 g/cm3) in the models instead of the density of the
thyroid gland, which according to ICRP publication 23 is
1.05 g/cm3 [33]. Dosimetric calculations performed with
a 3% mass concentration of 127I (stable iodine) homoge-
nously distributed within the follicle lumens only showed
a small difference for 211At [19], and after normalisation
of the mass for the follicle cell nuclei this difference would
be even less. Other assumptions regarding the thyroid
Table 2 S values for radioiodine in the human multiple thyroid models
Source compartment r1 r2 S value Relative contribution
a Relative contributionb Relative contributionc
(μm) (μm) (Gy/Bq·s) (%) (%) (%)
123I
Lumen 1 0 75 2.54E-07 9.6 15.0 -
Cell layer 1 75 85 1.60E-06 27.6 - 77.3
Cell layer 2a 85 95 2.77E-07 6.1 - 16.9
Lumen layer 2 95 245 4.23E-08 52.7 82.0 -
Cell layer 2b + 3a 245 265 5.86E-09 2.1 - 5.8
Lumen layer 3 265 415 3.97E-10 1.9 2.9 -
Cell layer 3b 415 425 7.50E-12 0.0 - 0.0
100 100 100
125I
Lumen 1 0 75 1.37E-07 7.7 93.6 -
Cells layer 1 75 85 3.21E-06 82.5 - 89.9
Cells layer 2a 85 95 2.85E-07 9.3 - 10.1
Lumen layer 2 95 245 2.86E-10 0.5 6.4 -
Cell layer 2b 245 255 0.00E+00 0.0 - 0.0
100 100 100
131I
Lumen 1 0 75 1.03E-06 5.7 6.9 -
Cells layer 1 75 85 1.98E-06 5.0 - 30.0
Cells layer 2a 85 95 1.02E-06 3.3 - 19.6
Lumen layer 2 95 245 1.44E-07 26.4 31.6 -
Cells layer 2b + 3a 245 265 5.14E-08 2.6 - 15.8
Lumen layer 3 265 415 2.36E-08 16.4 19.7 -
Cells layer 3b + 4a 415 435 1.35E-08 1.9 - 11.6
Lumen layer 4 435 585 7.68E-09 11.9 14.3 -
Cells layer 4b + 5a 585 605 5.39E-09 1.5 - 9.0
Lumen layer 5 605 755 3.28E-09 9.0 10.8 -
Cells layer 5b + 6a 755 775 2.08E-09 1.0 - 5.8
Lumen layer 6 775 925 1.31E-09 5.6 6.8 -
Cells layer 6b + 7a 925 945 9.70E-10 0.7 - 4.0
Lumen layer 7 945 1,095 6.81E-10 4.2 5.1 -
Cells layer 7b + 8a 1,095 1,115 3.67E-10 0.4 - 2.1
Lumen layer 8 1,115 1,265 3.30E-10 2.8 3.3 -
Cells layer 8b + 9a 1,265 1,285 2.21E-10 0.3 - 1.7
Lumen layer 9 1,285 1,435 1.12E-10 1.2 1.5 -
Cell layer 9b 1,435 1,445 6.30E-11 0.1 - 0.3
100 100 100
The S values for the innermost follicle cell nuclei from radioiodine homogeneously distributed in the different source compartments in the human multiple
thyroid follicle models (spherical compartments with r1 = inner radius and r2 = outer radius). The relative contributions to the mean absorbed dose to the
innermost follicle cell nuclei from each compartment are shown for three radionuclide distributions: for 123I with two surrounding layers of follicles contributing,
125I with one surrounding layer of follicles contributing, and 131I with eight surrounding layers of follicles contributing. Follicle layers beyond these contributed
with <1%. aRadioiodine homogeneously distributed within the follicle lumens and follicle cells (the entire thyroid model). bRadioiodine homogeneously distributed
within the follicle lumens. cRadioiodine homogeneously distributed within the follicle cells.
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Figure 3 Mean absorbed dose for different distributions of radioiodine in the human multiple follicle model. The mean absorbed dose
to the central follicle cell nuclei in the human multiple thyroid follicle model for different relations in radioiodine concentration (homogeneous in
each compartment) between follicle lumens and/or follicle cells for (a) 123I, (b) 125I and (c) 131I. The values indicate total mean absorbed dose
(blue bars, numbers), and the contribution to the mean absorbed dose from the follicle lumen (red bars) and from the follicle cells (green bars).
The error bars indicate the standard deviation of the mean value (SD).
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estimate that the assumptions in the dosimetrical calcula-
tions, such as limitations in nuclear decay data and trans-
port physics used by the Monte Carlo code only contribute
to a minor extent to the results. The conventional AE
spectrum from ICRP 107 was used in the calculations [26]
and have been regarded adequate when calculating
absorbed doses to regions with diameters larger than 1 μm
[34], and AE with initial kinetic energy lower than 1 keV
(the lowest cutoff energy for electrons in MCNPX 2.6.0)
were assumed to be fully absorbed within the source vol-
ume. This assumption is realistic since experiments have
shown that electrons with a kinetic energy of 1 keV have a
range of about 61 nm in unit density matter [32], verified
by calculations: absorbed fraction very close to unity for
unit density water spheres with radius of 2 μm for monoe-
nergetic 1 keV electrons [35]. Bremsstrahlung generated by
the electrons was not accounted for in the Monte Carlocalculations, but the contribution was low in this applica-
tion (for 1 MeV electrons, only about 0.7% of the kinetic
energy is transferred to bremsstrahlung in liquid water, and
this fraction is even less for lower kinetic energies [36]).
The contribution from 131mXe was not considered in the
dosimetric calculations for 131I, which would result in an
underestimation of the S value to the cell nucleus of about
3.6% for 131I homogenously distributed in an 8-μm cell nu-
cleus and about 1.5% for a homogenous distribution in a
150-μm diameter lumen (unpublished data). Furthermore,
the contribution from the xenon daughter is probably less
significant due to the short retention in the thyroid gland
because of its gaseous state [23].
For 123I, the contributions from the 123Te and 123mTe
daughters were not included in the dosimetric calcula-
tions due to a very long half-life and low yield, respect-
ively. Furthermore, the effects of the charge of the
tellurium atoms (average charge of about +9 [37] due to
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AE) were not considered. Otherwise, such charged atoms
may produce ionizations and excitations in the immediate
vicinity of the decay site [37], which could enhance the
biological effect when covalently bound to the DNA [38].
With 123I and 125I homogeneously distributed within
the follicle cell nucleus, the S value was 2.3 times higher
for 125I than that for 123I in the mouse, rat and human
models, a result in accordance with similar calculations
for a 10-μm diameter tissue sphere, excluding charge
neutralisation [37].
Biodistribution studies performed on mice, rats and
guinea pigs have shown that the highest uptake of radio-
iodide was in the thyroid gland, with the highest concen-
tration occurring around 18 to 24 h after injection
[39-41], while the maximal concentration is obtained
after approximately 1 to 2 days in normal humans [42].
Preclinical studies have shown that radioiodide is rapidly
transported through the follicle cell cytoplasm. At early
time-points, radioiodine appears as rings peripherally in
the follicle lumen close to the apical cell surface [43-46],
and thereafter the radioiodine is more homogeneously
distributed in the follicle lumen [45,46]. However per-
ipheral rings have been observed as long as 99 days after
injection [46]. The specific activity was initially highest
in the smallest follicles but became independent of fol-
licle size with time [45]. In the human model, the S value
for 123I, 125I and 131I distributed on the apical follicle cell
surface was 2.2, 5.9 and 1.5 times higher than for a
homogeneous distribution within the follicle lumen, re-
spectively. Due to the much shorter half-life of 123I (13 h),
the fraction of decays in the follicle cells and at the apical
surface would be highest for 123I, indicating a possible
higher absorbed dose when biokinetic data are considered.
The MIRD formalism assumes a homogeneous distri-
bution of the radionuclide within the source compart-
ment when determining the mean absorbed dose.
Compared with our results, the mean absorbed dose cal-
culated according to MIRD formalism (Equation 1) and
nuclear decay data was lower, with the largest difference
of 18% for 125I, and the smallest of 4% for 131I. This
comparison together with the dosimetric data obtained
for inhomogeneous distribution shows the importance
of taking the range of the emitted particles into account.
For 125I, the emitted low-energy AE and CE, with a
range of up to 23 μm in water [36], could contribute to
a heterogeneous absorbed dose distribution, and about
90% of the absorbed dose originates from the follicle it-
self. The high-energy β particles emitted by 131I, with a
range of up to 2.1 mm in water [24], contribute to a
cross-fire effect with contributions from eight surround-
ing layers of follicles, which results in a more homoge-
neous absorbed dose distribution, and only about 11% of
the mean absorbed dose originates from the follicleitself. For 123I, the emitted low-energetic AE and some-
what higher-energetic CE, the mean absorbed dose was
about 9% higher than that according to MIRD formal-
ism. The absorbed dose is then a combination between
heterogeneous absorbed dose distribution from the very
short-ranged AE and the more homogeneous absorbed
dose distribution from the more long-ranged CE, and
about 38% of the mean absorbed dose originates from
the follicle itself. Furthermore, in the peripheral regions
of the thyroid gland where fewer surrounding follicles
contribute, the absorbed dose may be lower and more het-
erogeneous. This effect would be largest for 131I with eight
surrounding follicle layers contributing and could lead to
a reduced mean absorbed dose by up to about 45%.
For radioiodine homogeneously distributed only within
the follicle lumens, the mean absorbed dose was 0.80,
0.11 and 0.98 Gy, respectively, for 123I, 125I and 131I,
compared with 1 Gy calculated with MIRD formalism
and nuclear decay data for radioiodine homogenously
distributed within both follicle cells and lumens. Thus,
the MIRD formalism overestimates the mean absorbed
dose for 123I and 125I.
Conclusions
This study clearly demonstrates the importance of using
more detailed dosimetric methods and models than MIRD
formalism for radioiodine within the thyroid. For radioio-
dine homogeneously distributed in the follicle cells and lu-
mens, calculations for our human multiple follicle model
gave up to 18% higher mean absorbed dose. For radioio-
dine homogeneously distributed in the follicle lumens only,
our calculations gave up to 90% lower mean absorbed dose
for 125I (20% lower for 123I, and 2% lower for 131I).
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